www.tnsmi-cmag.com – GLP-1 investment is accelerating as Bengaluru-based OneSource Specialty Pharma maps out an ambitious journey to $500 million in revenue by FY28, positioning itself at the crossroads of a historic patent cliff and a once-in-a-generation therapeutic boom in obesity and diabetes care.

GLP-1 investment and the rise of OneSource Pharma

OneSource Specialty Pharma, recently demerged from Strides Pharma in 2024, is emerging as a focused contract development and manufacturing organization (CDMO) with one clear strategic priority: capturing value from the global GLP-1 wave. The company is aligning capacity, capital, and partnerships toward this goal, betting that the upcoming expiry of semaglutide patents and the rapid growth of GLP-1 agonists will unlock an unprecedented opportunity for scaled, high-margin pharmaceutical services.

For readers, this is more than a single corporate growth story. It is a case study in how specialized pharma players in India are repositioning themselves within global supply chains at a time when regulators, payers, and patients are all converging around innovation in metabolic disease. Understanding this pivot sheds light on where capital will likely flow, how margins may evolve, and what competition might look like in the next five years.

Semaglutide patent cliff: the catalyst behind GLP-1 investment

The core strategic backdrop to OneSource Pharma’s plan is the approaching patent expiry of semaglutide, the active ingredient in Novo Nordisk’s blockbuster brands Ozempic and Wegovy. As these patents approach their end in key markets over the next decade, the industry expects a wave of generic and biosimilar entries, depending on local regulatory classifications and data exclusivity frameworks.

Contrary to popular belief, patent expiry does not simply trigger a price war; it often reshapes entire manufacturing ecosystems. Innovator companies reassess supply partnerships, while generic and specialty players scale up formulation, fill-finish, and packaging capabilities. This is precisely where a nimble CDMO like OneSource can insert itself, providing high-quality, compliant capacity for companies seeking to enter – or expand within – the GLP-1 category.

From an investor’s lens, the patent cliff is not just a risk to incumbents but a powerful driver of GLP-1 investment downstream. CDMOs that can demonstrate regulatory robustness, injectable expertise, and cost efficiency may capture recurring, multi-year revenue streams anchored in long-term supply contracts.

Inside OneSource’s $500M revenue and 40% EBITDA ambition

OneSource’s projection of $500 million in revenue by FY28, coupled with a targeted 40% EBITDA margin, signals a high-confidence strategy built around premium service offerings rather than pure volume. These numbers, if realized, would position the company among the more profitable mid-sized pharmaceutical service players in emerging markets.

Readers should pay attention to three underlying levers driving these projections:

• Specialization in injectables and complex formulations: GLP-1 therapies are typically injectable biologics or complex peptides, requiring strict cold-chain logistics, advanced fill-finish capabilities, and high-bar cGMP compliance. A CDMO that specializes in such dosage forms can command better pricing and longer contracts.
• Demerger-driven focus: As a demerged entity from Strides Pharma, OneSource is no longer constrained by a diversified corporate agenda. It can direct management attention, R&D, and capital expenditure squarely toward growth opportunities tied to obesity, diabetes, and adjacent metabolic segments.
• Strategic timing: The window between patent protection and the full flood of generics is narrow but lucrative. By investing now in capacity and compliance, OneSource aims to be ready for the first waves of GLP-1 follow-on products rather than playing catch-up.

While the $500 million and 40% EBITDA targets remain forward-looking statements, they align with what we have seen in other successful CDMOs that married capacity expansion with high-value, late-stage and commercial supply contracts in specialized therapeutic categories.

Global GLP-1 market dynamics: why the investment rush is rational

To understand why GLP-1 investment is drawing such intense attention, we need to step back and look at the broader market landscape. GLP-1 receptor agonists, originally developed to manage type 2 diabetes, have rapidly become a cornerstone therapy for obesity management worldwide. According to multiple industry forecasts, the global market for GLP-1-based obesity and diabetes therapies could reach tens of billions of dollars annually over the next decade.

Reports from leading financial and healthcare analysts, including coverage by Reuters on the impact of Wegovy and Ozempic, highlight several structural drivers:

• Rising global prevalence of obesity and type 2 diabetes, especially in emerging markets.
• Strong clinical data demonstrating sustained weight loss and cardiometabolic benefits.
• Growing payer acceptance as real-world outcomes data accumulates.
• Innovation in oral formulations and next-generation GLP-1/GIP or dual agonist combinations.

These forces collectively support long-term demand visibility. Even when semaglutide and similar molecules face generic competition, total molecule utilization is likely to rise, not fall. That scenario favors efficient manufacturers and CDMOs capable of supporting both innovators and generic entrants.

India’s CDMO edge in the GLP-1 era

India’s pharmaceutical ecosystem has spent decades building a reputation as the “pharmacy of the world” in generics. The GLP-1 cycle presents a chance to extend that reputation into higher-value, technology-intensive services. Mid-sized players like OneSource, born from established pharma houses but laser-focused on services, stand to benefit from this structural shift.

Several macro factors support India as a hub for GLP-1 manufacturing and development:

• Cost-effective yet qualified workforce, with deep experience in injectable and peptide manufacturing.
• Regulatory familiarity with the US FDA, EMA, and other global agencies, given India’s long-standing export presence.
• Government push for domestic value addition in pharma and biologics, through incentives and policy support.
• Existing infrastructure built around APIs, formulations, and contract manufacturing, which can be upgraded for GLP-1 needs.

For readers tracking Indian pharma, this shift blurs the classic distinction between generic manufacturers and services providers. Companies like OneSource increasingly operate as integrated partners – offering formulation development, clinical supplies, commercial manufacturing, and even lifecycle management support around high-growth therapeutic classes.

To explore how Indian pharma is evolving more broadly, readers can follow our ongoing coverage under Pharma and related industry trend analyses.

Seven critical insights from OneSource’s GLP-1 investment strategy

Beyond the headline numbers, OneSource’s move offers seven critical insights into how the next phase of the GLP-1 story may unfold for manufacturers and investors alike.

1. GLP-1 investment hinges on injectables excellence

Most GLP-1 therapies today are delivered via subcutaneous injection, often through sophisticated pen devices or auto-injectors. CDMOs aspiring to win business in this space must demonstrate:

• High-speed aseptic fill-finish lines.
• Container-closure integrity for cartridges and vials.
• Capability to integrate with device partners for combination products.

OneSource’s ambition implies that it is either building or expanding precisely these competencies. This creates a barrier to entry for smaller or less capitalized competitors, which may struggle with the upfront investment and qualification timelines required.

2. Timing GLP-1 investment around the patent cycle

The patent cliff for semaglutide and similar molecules does not arrive overnight; it unfolds across jurisdictions and indications. Early movers can secure development and scale-up work for generic and biosimilar candidates years before final loss of exclusivity. OneSource’s FY28 revenue target suggests an expectation that key contracts and volume ramps will crystallize in the mid- to late-2020s.

Investors should consider this timing carefully. Revenue may not grow linearly. Instead, we are likely to see stepwise increases coinciding with product approvals, market launches, and the onboarding of new clients seeking reliable GLP-1 capacity.

3. Margin profile reflects premium positioning

A targeted 40% EBITDA margin is well above what commodity generics businesses typically deliver. Such margins are more consistent with specialized CDMOs serving regulated markets with complex products. The implicit message: GLP-1 investment is not just about chasing volume; it is about moving up the value chain into technically demanding, compliance-intensive work where clients prioritize reliability over rock-bottom pricing.

4. CDMO models align with de-risked growth

Using a CDMO platform to participate in the GLP-1 opportunity spreads risk across multiple clients and product pipelines. Rather than betting on a single molecule or brand, OneSource can support several innovators, generic companies, and regional players targeting different geographies and patient segments. This diversification can stabilize revenues even as individual products face competitive pressure.

5. Data, digital, and quality systems as silent differentiators

While capacity expansions capture headlines, the most successful GLP-1 manufacturing partners are likely to distinguish themselves through robust quality systems, data integrity, and digital traceability. Regulatory bodies increasingly scrutinize not just physical plants but also electronic records, serialization, and batch history. CDMOs that invest early in digital QMS, advanced analytics, and seamless audit readiness will have an edge.

6. Sustainability and ESG in GLP-1 supply chains

As global attention turns to responsible manufacturing, environmental, social, and governance (ESG) factors will shape long-term GLP-1 supply partnerships. Efficient energy use, waste reduction, and ethical labor practices can enhance the attractiveness of CDMO partners for multinational pharma companies under investor pressure to improve their ESG scores.

Readers interested in how sustainability intersects with pharma and healthcare can explore our coverage under Healthcare, where we examine ESG disclosures, green manufacturing trends, and patient-access initiatives.

7. India’s evolving role in global metabolic health

Finally, OneSource’s moves underscore India’s increasingly central role in addressing global metabolic health challenges. With one of the world’s highest numbers of people living with diabetes and obesity, India is both a vital market and a critical production base. As GLP-1 therapies scale, India’s combination of scientific talent, manufacturing infrastructure, and cost efficiency will draw more GLP-1 investment from global partners seeking reliable, diversified supply chains.

Risks and realities behind the bullish GLP-1 narrative

While the opportunity is compelling, readers should also weigh the risks inherent in such a concentrated strategy:

• Regulatory risk: Any deviation from quality norms in injectables can lead to plant shutdowns, warning letters, or import alerts, eroding hard-won reputation and contracts.
• Competition: Other global CDMOs and large integrated manufacturers are also scaling GLP-1 capacity, especially in Europe, North America, and East Asia.
• Pricing pressure: As generics and biosimilars proliferate, downstream pricing pressure may eventually cascade up the value chain, challenging margins unless efficiency improves.
• Innovation risk: Breakthroughs such as newer dual or triple agonists or alternative mechanisms of action could shift market share away from established GLP-1 molecules more rapidly than expected.

Balanced analysis requires acknowledging that high growth projections rely on effective execution, disciplined capital allocation, and proactive risk management. For OneSource and its peers, the next 3–5 years will test whether strategic vision can be translated into operational excellence.

What readers and investors should watch next

For stakeholders monitoring GLP-1 investment across Asia and beyond, a few indicators will be particularly revealing:

• The pace of capacity announcements and capex deployment by OneSource and comparable CDMOs.
• Regulatory approvals for GLP-1 generics and biosimilars in major markets.
• Long-term supply agreements disclosed by innovators and generics players, especially those citing Indian partners.
• Emerging policy responses from regulators and payers as GLP-1 utilization expands into broader obesity and cardiometabolic indications.

Additionally, how OneSource leverages its demerger from Strides – in terms of governance, capital structure, and partnerships – will influence whether it can fully exploit this inflection point. The GLP-1 era rewards agility, but it also demands strong process discipline and continuous reinvestment in technology and talent.

Conclusion: GLP-1 investment as a defining test for India’s next-gen CDMOs

The surge in GLP-1 investment is reshaping not only obesity and diabetes treatment paradigms but also the structure of global pharmaceutical manufacturing. OneSource Specialty Pharma’s bold target of $500 million in revenue and 40% EBITDA margins by FY28 captures both the promise and the pressure of this transformation. For India’s CDMO sector, GLP-1 is more than a lucrative therapeutic category; it is a proving ground for whether the industry can move decisively into higher-value, innovation-linked services.

Readers who follow this space closely will recognize that the coming years will likely be defined by a handful of pivotal outcomes: who scales first with quality, who secures durable long-term contracts, and who adapts fastest as science, policy, and patient expectations evolve. In that sense, OneSource’s journey offers a window into the broader future of global pharma – a future in which thoughtful, strategically timed GLP-1 investment could separate the next generation of leaders from the rest of the field.